Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University College, London
Compass Therapeutics
Emory University
University of Pittsburgh
National Cancer Institute (NCI)
Pfizer
Zhongnan Hospital
Korea University Anam Hospital
GlaxoSmithKline
University of Colorado, Denver